drugset / Trial / NCT07241169
The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4
Phase 0
Recruiting
9 enrolled
Zhongshan Ophthalmic Center, Sun Yat-sen University
Chigenovo Co., Ltd · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the preliminary safety of monocular and single subretinal injection of ZVS106e injection in the treatment of patients with hereditary retinal degeneration (ABCA4-IRDS) caused by ABCA4 biallelic mutations.
Timeline
- Start
- 2025-12-29
- Primary completion
- 2028-11-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZVS106e | Gene therapy (AAV / viral vector) | — | Other |